REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

01 ноя 2022 16:05:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

22 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

01 сен 2022 16:05:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

31 авг 2022 16:05:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

09 авг 2022 16:02:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

28 июл 2022 16:02:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

22 июл 2022 16:02:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

19 июл 2022 22:41:52 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

19 июл 2022 16:01:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

13 июл 2022 07:00:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

28 июн 2022 07:00:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

09 июн 2022 16:02:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

09 май 2022 16:02:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

21 апр 2022 16:05:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

09 мар 2022 07:30:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

01 мар 2022 16:05:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

28 фев 2022 16:05:01 Источник Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022

22 фев 2022 16:05:00 Источник Nasdaq GlobeNewswire

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

03 фев 2022 07:30:00 Источник Nasdaq GlobeNewswire

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

11 янв 2022 14:15:00 Источник Nasdaq GlobeNewswire